
    
      -  Primary objectives: To determine the proportion of patients with progression- free
           survival after 6 months of intensive dose temozolomide treatment alone or in combination
           with thalidomide in patients with recurrent glioblastoma multiforme after standard
           therapy.

        -  Secondary objectives: To assess the effects on tumor growth. To determine the time to
           disease progression. To determine the proportion of patients with progression- free
           survival. To assess the safety of intensive dose temozolomide treatment alone or in
           combination with thalidomide.

        -  Explorative evaluations: To assess health related Quality of Life. To assess cognitive
           functioning. To compare the two treatment arms in terms of efficacy and safety.
    
  